NASDAQ:DCPH - Deciphera Pharmaceuticals Stock Price, Forecast & News

Deciphera Pharmaceuticals' stock was trading at $44.42 on March 11th, 2020 when Coronavirus (COVID-19) reached pandemic status according to the World Health Organization. Since then, DCPH stock has decreased by 7.3% and is now trading at $41.17. View which stocks have been mosted impacted by Coronavirus.

13 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Deciphera Pharmaceuticals in the last year. There are currently 1 hold rating and 12 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View analyst ratings for Deciphera Pharmaceuticals.

Deciphera Pharmaceuticals is scheduled to release its next quarterly earnings announcement on Thursday, May 14th 2020. View our earnings forecast for Deciphera Pharmaceuticals.

Deciphera Pharmaceuticals Inc (NASDAQ:DCPH) posted its quarterly earnings results on Monday, March, 9th. The company reported ($1.31) earnings per share (EPS) for the quarter, missing the consensus estimate of ($1.13) by $0.18. View Deciphera Pharmaceuticals' earnings history.

13 equities research analysts have issued 12 month price objectives for Deciphera Pharmaceuticals' stock. Their forecasts range from $34.00 to $84.00. On average, they anticipate Deciphera Pharmaceuticals' stock price to reach $65.38 in the next year. This suggests a possible upside of 58.8% from the stock's current price. View analysts' price targets for Deciphera Pharmaceuticals.

Media headlines about DCPH stock have been trending positive this week, InfoTrie Sentiment Analysis reports. The research group scores the sentiment of news coverage by reviewing more than six thousand blog and news sources in real-time. The firm ranks coverage of public companies on a scale of negative five to positive five, with scores closest to five being the most favorable. Deciphera Pharmaceuticals earned a media sentiment score of 3.0 on InfoTrie's scale. They also gave headlines about the company a news buzz of 0.0 out of 10, indicating that recent news coverage is extremely unlikely to have an impact on the stock's share price in the near term. View the latest news aboutDeciphera Pharmaceuticals.

Deciphera Pharmaceuticals saw a decline in short interest in March. As of March 13th, there was short interest totaling 2,610,800 shares, a decline of 8.1% from the February 27th total of 2,840,000 shares. Based on an average trading volume of 681,200 shares, the short-interest ratio is presently 3.8 days. Currently, 7.5% of the company's stock are sold short. View Deciphera Pharmaceuticals' Current Options Chain.

Some companies that are related to Deciphera Pharmaceuticals include Ono Pharmaceutical (OPHLF), Elanco Animal Health (ELAN), Teva Pharmaceutical Industries (TEVA), Beigene (BGNE), Sarepta Therapeutics (SRPT), Mylan (MYL), Catalent (CTLT), Ionis Pharmaceuticals (IONS), Dr.Reddy's Laboratories (RDY), Perrigo (PRGO), ACADIA Pharmaceuticals (ACAD), Jazz Pharmaceuticals (JAZZ), Horizon Therapeutics (HZNP), Ascendis Pharma A/S (ASND) and Bausch Health Companies (BHC).

Based on aggregate information from My MarketBeat watchlists, some companies that other Deciphera Pharmaceuticals investors own include Ionis Pharmaceuticals (IONS), Allena Pharmaceuticals (ALNA), Immunomedics (IMMU), Viking Therapeutics (VKTX), Alibaba Group (BABA), Amarin (AMRN), Arrowhead Pharmaceuticals (ARWR), Cytokinetics (CYTK), Fate Therapeutics (FATE) and Global Blood Therapeutics (GBT).

(DCPH) raised $101 million in an initial public offering (IPO) on Thursday, September 28th 2017. The company issued 6,300,000 shares at $15.00-$17.00 per share. J.P. Morgan and Piper Jaffray acted as the underwriters for the IPO and JMP Securities and Nomura were co-managers.

Deciphera Pharmaceuticals trades on the NASDAQ under the ticker symbol "DCPH."

Shares of DCPH can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.

One share of DCPH stock can currently be purchased for approximately $41.17.

Deciphera Pharmaceuticals has a market capitalization of $2.29 billion and generates $25 million in revenue each year. The company earns $-192,260,000.00 in net income (profit) each year or ($4.48) on an earnings per share basis. Deciphera Pharmaceuticals employs 112 workers across the globe. View additional information about Deciphera Pharmaceuticals.

The official website for Deciphera Pharmaceuticals is http://www.deciphera.com/.

Deciphera Pharmaceuticals' mailing address is 500 Totten Pond Road, Waltham MA, 02451. The company can be reached via phone at 781-209-6400 or via email at [email protected]